Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Qulipta price, strengths & recalls

Brand of atogepant (generic)

Pharmacies pay $1,150.36 for 30 tablets of Qulipta 10 mg tablet this week, and from $1,150.36 to $1,153.27 across its 3 priced strengths and forms. Its official label last changed on February 10, 2026.

Brand
Pharmacies pay$1,150.36for 30 tablets of 10 mg tabletNo change in 4 weeks
Fair cash price
$1,333.41
Strengths
3
Makers
1
Updated
Nov 11

Qulipta price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
10 mg tablet Brand$38.35$1,150.36 / 30 tabletsNo change+4.9%
30 mg tablet Brand$38.37$1,151.02 / 30 tabletsNo change+4.9%
60 mg tablet Brand$38.44$1,153.27 / 30 tabletsNo change+4.9%

The lowest cost per tablet is 10 mg tablet at $38.35. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Qulipta vs generic atogepant

There is no generic version of Qulipta on the market yet. Its last listed patent or exclusivity runs to February 27, 2043 - generics often follow, though court cases and settlements can move the date either way.

GenericAtogepant prices

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
No ongoing recallsNone on record

What did you pay for qulipta? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedFebruary 10, 2026
Version19 of 14
EffectiveSep 30, 2025
Read the label

These highlights do not include all the information needed to use QULIPTA safely and effectively. See full prescribing information for QULIPTA. QULIPTA® (atogepant) tablets, for oral useInitial U.S. Approval: 2021

Recent major changes (as listed on the label)

Dosage and Administration (2.2) | 9/2025 |

Warnings and Precautions (5.2, 5.3) |

3/2025 |

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA215206 · Abbvie
First approved
September 28, 2021 (5 years ago)
Latest approved change
September 30, 2025
Approved label
PDF, Oct 1, 2025
Generic makers
None on the market
Last patent listed
February 27, 2043
Exclusivity ends
September 28, 2026 (ended)

Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.

Qulipta questions

How much does qulipta cost without insurance?

Pharmacies pay about $1,150.36 for 30 tablets of qulipta 10 mg tablet ($38.35 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $1,333.41. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Qulipta?

Yes: atogepant. Compare atogepant prices.

Is qulipta in shortage?

No shortage is reported for qulipta right now. We check the national shortage list every day.

Has qulipta been recalled?

No recalls are on record for qulipta.

When did the qulipta label last change?

The official label was last updated on February 10, 2026 (version 19). See what changed.

Talk about qulipta

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.